Skip to main content
Quest Diagnostics

Estimating Risk of Severe COVID-19 Based on Initial Biomarker Assessment

Joint Statistical Meetings

JSM 2023

Toronto, Ontario, Canada, Aug 5-10, 2023

Poster presentation: Estimating Risk of Severe COVID-19 Based on Initial Biomarker Assessment

Authors: Bi C, Kroll MH, Salm AE, Szymanski J, Goldstein Y, Wolgast LR, Rosenblatt G, Fox A, Kapoor H

Specialty: Infectious Disease, COVID-19

Related content

Conference Presentation
Prediction of Severe COVID-19 Based on Routine Biomarker Assessment
Publication
SARS-CoV-2 Spike-Protein Targeted Serology Test Results and Their Association With Subsequent COVID-19-Related Outcomes
Audio Podcast
Commitment to Employee Health: A Blueprint for Wellness
Publication
Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.